Completed PHASE2 INTERVENTIONAL 2-arm NCT01994707

Remote Ischemic Preconditioning of Human Myocardium

Sponsor: Medical University of Silesia

Conditions Apoptotic DNA Damage Coronary Artery Bypass Graft Triple Vessel

Interventions Placebo Remote ischemic preconditioning

Updated 6 times since 2017 Last updated: Jan 10, 2018 Started: Aug 31, 2013 Primary completion: Jan 10, 2016 Completion: Apr 27, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Apoptotic DNA Damage and Coronary Artery Bypass Graft Triple Vessel, this trial is completed. The trial is conducted by Medical University of Silesia and has accumulated 6 data snapshots since 2013. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2018 — Jun 2018 [monthly]

Completed PHASE2

Status: Recruiting → Completed

▶ Show 1 earlier version

Jan 2017 — Feb 2018 [monthly]

Recruiting PHASE2

First recorded

Aug 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Medical University of Silesia
National Science Centre, Poland

Data source: Medical University of Silesia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Katowice, Poland